randomized clinical trial on actinic keratoses of the face

Phase 3

• Conditions: actinic keratoses; L57.0

• Registration Number: RBR-2bqy9p
• Lead Sponsor: niversidade Federal do Rio Grande do Sul

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-06-07
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

patients with actinic keratosis on face with minimum age of eighteen years no history preliminary melanoma

Exclusion Criteria

renal transplanted patients in use of immunosuppressors history of previous melanoma with health change

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
100% remission of actinic keratosis of the face is expected to be complete with the use of microneedle reduction with the usual 15-day treatment time with 5-fluorouracil in drug delivery. besides reducing the side effects and the number of lesions

Secondary Outcome Measures

Name	Time	Method
partial remission of actinic keratoses<br>total number of lesions at the end of the study